BMY BRISTOL MYERS SQUIBB CO Insider Trading

Bristol Myers CFO David Elkins sold 30,000 shares (30.0K shares) for $1,850,016.45 on 2026-04-01, reducing holdings to 159,248 shares

David V Elkins, EVP and Chief Financial Officer, executed two separate sales totaling 30,000 shares at an average price of $61.67, realizing $1,850,016.45. This represents a 15.9% reduction in his post-transaction holdings from 189,248 shares. The sales occurred at prices slightly above the current market price of $59.60 and near the 52-week high of $62.37, though the stock has declined 2.6% over the past 30 days and is now 4.4% below its 52-week peak. His prior sell at BMY on 2025-09-02 achieved a 90-day return of 3.9%, indicating the stock subsequently rose after that transaction. With Bristol Myers trading at a P/E of 5.51 and reporting recent quarterly net income of $2,201,000,000.00 on revenue of $12,222,000,000.00, the transaction provides no evidence of strategic concern about near-term fundamentals, though the substantial share reduction warrants monitoring as part of the CFO's broader capital allocation decisions.

CFO David Elkins sells 56,000 BMY shares ($2.7M) at $47.33, reducing stake to 167,379 shares (-25.1%)

David Elkins, EVP and Chief Financial Officer of Bristol Myers Squibb, divested 56,000 shares (56.0K shares) for $2,650,480.00 ($2.7M), reducing his post-transaction holdings to 167,379 shares (167.4K shares) from 223,379 shares (223.4K shares). This represents a substantial reduction of -25.1% in his shareholding. The sale occurred at $47.33, which is below the current price of $47.50 and materially below the 52-week high of $63.11, reflecting a -24.7% drawdown from peak valuation. This transaction is noteworthy given that Bristol Myers Squibb was unprofitable over its most recent full fiscal year despite posting $12,269,000,000.00 ($12.3B) in quarterly revenue and $1,310,000,000.00 ($1.3B) in quarterly net income, creating a disconnect between operational results and annual profitability that merits investor scrutiny of underlying business performance and capital allocation.

Hirawat (EVP, Chief Med. Officer) bought 4,250 BMY shares at $47.58 on 2025-04-25; holdings now 83,513 shares.

Hirawat purchased 4,250 shares of Bristol Myers Squibb at $47.58, increasing holdings by 5.4% to 83,513 shares total. At the current price of $49.22, the stock trades -22.0% from its 52-week high and has declined -18.0% over the past 30 days. His prior two buys at BMY (2024-11-01 and 2025-02-14) both captured positive 30-day returns of 8.3% and 7.6% respectively, with the November trade posting a measurable 90-day gain of 8.2%. Across all tickers, his open-market buy track record shows a 100% 90-day win rate across 2 prior transactions with an average 90-day return of 8.2%, though that cross-ticker record should be distinguished from his BMY-specific history.

BMY CEO buys 2,000 shares at $55.05; holds 104.6K post-transaction; stock -7.9% from 52-week high.

Christopher S. Boerner, CEO of Bristol Myers Squibb, purchased 2,000 shares at $55.05 on 2025-02-20, increasing his holdings to 104.6K shares (+1.9%). His cross-ticker track record shows 2 prior open-market buys averaging +4.7% over 30 days and +2.8% over 90 days, with a 100% win rate. At BMY specifically, his prior 2 buys (both in late 2023) also posted positive 90-day returns of +4.5% and +4.8% respectively, indicating a consistent pattern of well-timed accumulation at this ticker. The current stock price of $55.83 sits -7.9% from the 52-week high of $60.60 and -2.2% over the past 30 days, providing a depressed entry point relative to recent range. However, the company's full-year net income was negative despite $11.9B in quarterly revenue and +7.3% annual growth, raising a question about profitability trajectory that context alone cannot resolve.

EVP Chief Medical Officer Hirawat buys 1.8K BMY shares at $54.84; prior BMY purchase gained +8.3% in 30d.

Samit Hirawat, EVP and Chief Medical Officer, purchased 1,823 shares of Bristol Myers Squibb at $54.84 on 2025-02-14 for $99,999.97, increasing his holdings to 63,932 shares. His prior open-market purchase at BMY on 2024-11-01 returned +8.3% over 30 days and +8.2% over 90 days, demonstrating timing accuracy in his previous BMY transaction. The current stock price of $54.98 is -9.3% from the 52-week high and -2.3% over the past 30 days, placing this purchase in a near-term downtrend. His cross-ticker trading history shows 1 prior buy with an average 90-day return of +8.2% and a 100% win rate, though that track record spans multiple tickers and may not predict performance at BMY specifically. The company reported $11.9B in quarterly revenue and $1.2B in net income, though full-year net income was negative, warranting investor scrutiny of the broader business trajectory.

EVP/Chief Medical Officer Hirawat Samit buys 1,830 BMY shares at $54.68; holdings rise to 62,109 shares.

Samit, serving as EVP and Chief Medical Officer responsible for drug development at Bristol Myers Squibb, purchased 1,830 shares on 2024-11-01 at $54.68, increasing his post-transaction holdings from 60,279 shares to 62,109 shares. The purchase price of $54.68 is 2.3% below the current market price of $55.95 and matches the 52-week low area, though the stock has recovered to its 52-week high of $55.95 since the transaction. The 3.0% increase in his shareholding represents a modest expansion of his position in a company trading at a P/E of 14.42 with trailing annual revenue declining 2.5% year-over-year, alongside $1.2B in net income on $11.9B in quarterly revenue. The transaction is neither large relative to his existing holdings nor reflective of a major equity exposure change, warranting routine monitoring rather than immediate strategic significance.